Specify a stock or a cryptocurrency in the search bar to get a summary
Mydecine Innovations Group Inc
MYCOFMydecine Innovations Group Inc., a biotechnology company, engages in the research, development, and commercialization of psilocybin products to treat mental health conditions. The company primarily focuses on treating nicotine addiction and post-traumatic stress disorder. Its lead product drug candidates include MYCO-005. The company also develops MYCO-006 and MYCO-007. Mydecine Innovations Group Inc. has a partnership with Applied Pharmaceutical Innovation for pharmaceutical drug discovery, research, and development on empathogenic and entactogenic compounds. The company was formerly known as NewLeaf Brands Inc. and changed its name to Mydecine Innovations Group Inc. in June 2020. Mydecine Innovations Group Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada. Address: 1075 West Georgia Street, Vancouver, BC, Canada, V6E 3C9
Analytics
WallStreet Target Price
–P/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures MYCOF
Dividend Analytics MYCOF
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History MYCOF
Stock Valuation MYCOF
Financials MYCOF
Results | 2019 | Dynamics |